

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Diagnosics Advisory Committee (DAC)

Minutes of the Meeting on 30 November 2017, 10.30 – 16.00

Level 1A City Tower, Piccadilly Plaza, Manchester M1 4BD

PRESENT:

Standing Committee members:

Dr Mark Kroese (Chair)
Professor Enitan Carrol
Dr Simon Fleming
Dr Jim Gray
Dr Shelley Rahman Haley
Professor Steve Halligan
Mr John Hitchman
Professor Christopher Hyde
Mr Patrick McGinley
Dr Michael Messenger
Dr Peter Naylor
Dr Dermot Neely
Mrs Alexandria Moseley
Professor Matt Stevenson

Standing Committee apologies:

Mr John Bagshaw
Dr Owen Driskell
Dr Steve Edwards
Dr Simon Richards
Professor Mark Sculpher
Professor Anthony Wierzbicki

NICE staff in attendance:

Mark Campbell, Associate Director, MTEP
Rebecca Albrow, Senior Technical Adviser, DAP
Frances Nixon, Technical Adviser, DAP
Christopher Pomfrett, Technical Adviser, MTEP
Donna Barnes, Project Manager, DAP
Alex Sexton, Administrator, DAP

Observing:

Ann Greenwood, Senior Medical Editor, NICE
Ian Mather, Business Analyst, NICE

Lydia Shears, Public Involvement Adviser, NICE
Katie Wyart, Medical Technology Implementation Manager, NICE

1. Introduction to the meeting

The Chair welcomed Committee members, observers and members of the public.

Apologies were noted.

2. Code of conduct for members of the public attending the meeting

The Chair explained the code of conduct to the members of the public attending this meeting.

3. Any other business

No other business was offered.

4. Minutes from the last Committee meeting

The Committee agreed the minutes from the 26 September 2017 Committee meeting.

5. NICE's advisory body guide to declaring a conflict of interest

The Chair drew the Committee's attention to NICE's Advisory Body Quick Guide for declaring conflicts of interest, the selection and routing criteria and the equalities statement.

Assessment of tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10)

External Assessment Group representatives: School of Health and Related Research (SchARR):

Alice Bessey, Research Assistant
Katy Cooper, Research Fellow
Sue Harnan, Research Fellow
Paul Tappenden, Reader

Specialist Committee members:

Dr Maria Bramley, Breast Surgeon
Dr John Graham, Consultant Oncologist
Linda Pepper, Lay member
Dr Deirdre Ryan, Consultant Cellular Pathologist
Dr Britta Stordal, Consultant Clinical Scientist
Professor Andrew Wardley, Consultant & MAHSC Professor in Medical Oncology

Specialist Committee members apologies:

Ursula Van Mann, Lay member

PART 1 AND PART 2 (open and closed parts of the meeting).

Part 1 – Open session

The Chair welcomed representatives from Agendia, Genomic Health UK, Myriad Genetics, Nanostring, and the Royal Marsden NHS Foundation Trust.

There were 6 public attendees.

The Chair asked Committee members to declare any relevant interests.

- Dr John Graham declared a non-specific personal financial interest, non-specific non-personal financial interests and non-specific personal non-financial interests; these interests did not preclude him from taking part in the meeting.
- Dr Michael Messenger declared non-specific non-personal financial interests and a non-specific personal non-financial interest; these interests did not preclude him from taking part in the meeting.
- Professor Matt Stevenson declared a specific personal non-financial interest; this interest did not preclude him from taking part in the meeting.

The Committee proceeded to discuss the clinical effectiveness and cost effectiveness of tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10).

The Committee was asked if there were any specific equality issues to consider in relation to this assessment.

The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

The Chair thanked the manufacturer representatives for their attendance, participation and contribution to the meeting.

End of Part 1

Part 2 – closed session

Agreement on the content of the Diagnostic Consultation Document (DCD) was discussed by the committee.

End of Part 2

Date, time and venue of next meeting:

Wednesday 10 January 2018 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BD.